Wu, C. E. et al. described a CMF regimen application in adjuvant chemotherapy of triple-negative breast cancer (TNBC), characterized with negative tests for oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) [267]. Here, ERBB2 is linked to triple-negative breast carcinoma.